News | August 06, 2014

PET/CT Using FDG-labeled Leucocytes May Detect Infection in Acute Pancreatitis

August 6, 2014 — A new clinical study diagnosing infection in patients with pancreatic fluid collections may swiftly and accurately rule out active infection in the body. As reported in the August issue of The Journal of Nuclear Medicine, this treatment may assist in bringing nuclear medicine to the forefront of clinical management.

Acute pancreatitis (AP) is a sudden inflammation of the pancreas. It can have severe complications and high mortality despite treatment. While mild cases of AP are often successfully treated with conservative measures, such as nil per os (NPO) and aggressive intravenous fluid rehydration, severe cases may require admission to the intensive care unit or even surgery to deal with complications of the disease process. Early detection of infection in AP affects the choice of treatment and clinical outcome.

"Documenting infection of pancreatic necrosis/pancreatic or peripancreatic fluid collections is one of the key questions in managing such patients. So far only fine needle aspiration under radiological guidance could establish that with limitations of invasive procedure and at times insufficient amount of aspirate," said Anish Bhattacharya, M.D., lead author of the study "PET/CT using 18F-fluorodeoxyglucose-labeled autologous leucocytes in the diagnosis of infected fluid collections in acute pancreatitis." He continued, "The present study, for the first time, gives evidence of a non-invasive investigation that can answer the question of infected pancreatic fluid collections. It even distinguishes two collections, one with and the other without infection. It could also be used to follow up with such patients after a radiological or endoscopic intervention."

In the study, researchers from the Postgraduate Institute of Medical Education and Research, Chandigarh, India, studied 41 patients — 28 male and 13 female — aged 21-69 with AP and radiological evidence of fluid collection in or around the pancreas. Leucocytes were separated from the patient's venous blood, labeled with 18F-fluorodeoxyglucose (FDG) and re-injected intravenously, followed by positron emission tomography/computed tomography (PET/CT) imaging two hours later. A final diagnosis of infection was based on microbiological culture of fluid aspirated from the collection. Patients were managed with supportive care and antibiotics; percutaneous drainage/laparotomy were performed when indicated.

Blood glucose, total leucocyte count, neutrophil count and leucocyte labeling efficiency varied from 83 to 212 (118±30) mg/100ml, 4600 to 24,200 (11648 ± 5376)/mm3, 55% to 90% (73 ± 10) and 31% to 97% (81 ± 17) respectively. Increased tracer uptake was seen in the collection in 12 out of 41 patients; 10 had culture-proven infection and underwent percutaneous drainage, while aspiration was unsuccessful in two. The scan was negative for infection in 29 patients (25 out of 29 fluid cultures negative for infection and aspiration unsuccessful in four). Sensitivity, specificity and accuracy of the scan were 100% in 35 patients in whom fluid culture reports were available.

"This research uses a new technique to diagnose infection occurring in patients with pancreatic fluid collections. The patient is spared empirical antibiotic therapy or radiological intervention followed by time-consuming microbiological work-up," noted Bhattacharya.

The search for the ideal infection imaging radiopharmaceutical agent/technique has continued for several decades now, noted Bhattacharya. "This study suggests that PET-CT using FDG-labeled leucocytes may be useful in swiftly and accurately detecting or ruling out active infection in any part of the body, bringing nuclear medicine to the forefront of clinical management in these situations. This would encourage researchers to identify more such techniques in future," he said.

For more information: jnm.snmjournals.org

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...